EDSS Change Relates to Physical HRQoL While Relapse Occurrence Relates to Overall HRQoL in Patients with Multiple Sclerosis Receiving Subcutaneous Interferon β -1a.

IF 2.2 Q3 CLINICAL NEUROLOGY
Multiple Sclerosis International Pub Date : 2015-01-01 Epub Date: 2015-07-05 DOI:10.1155/2015/631989
Barbara G Vickrey, Liesly Lee, Fraser Moore, Patrick Moriarty
{"title":"EDSS Change Relates to Physical HRQoL While Relapse Occurrence Relates to Overall HRQoL in Patients with Multiple Sclerosis Receiving Subcutaneous Interferon β -1a.","authors":"Barbara G Vickrey,&nbsp;Liesly Lee,&nbsp;Fraser Moore,&nbsp;Patrick Moriarty","doi":"10.1155/2015/631989","DOIUrl":null,"url":null,"abstract":"<p><p>Objective. To compare patterns of associations of changes in mental and physical health dimensions of health-related quality of life (HRQoL) over time with relapse occurrence and changes in Expanded Disability Status Scale (EDSS) scores in patients with relapsing multiple sclerosis (RMS). Methods. This 24-month, phase IV, observational study enrolled 334 patients with RMS who received interferon β-1a 44 μg or 22 μg subcutaneously three times weekly. At each 6-month visit, patients completed the Multiple Sclerosis Quality of Life-54 (MSQOL-54) and site investigators assessed EDSS and recorded relapse occurrence. A generalized linear model procedure was used for multivariable analyses (per protocol) that explored unique associations of EDSS score change and relapse occurrence with MSQOL-54 physical health composite score (PCS) and mental health composite score (MCS). Results. HRQoL improved over 2 years among those who completed the study. Occurrence of ≥1 relapse was significantly associated with lower MSQOL-54 PCS and MCS. Changes in EDSS score were significantly associated with MSQOL-54 PCS, but not MCS. Conclusions. HRQoL assessments, particularly those that examine mental health, may provide information on the general health status of patients with RMS that would not be recognized using traditional clinician-assessed measures of disease severity and activity. This trial is registered with ClinicalTrials.gov; identifier: NCT01141751. </p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2015 ","pages":"631989"},"PeriodicalIF":2.2000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/631989","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2015/631989","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/7/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 9

Abstract

Objective. To compare patterns of associations of changes in mental and physical health dimensions of health-related quality of life (HRQoL) over time with relapse occurrence and changes in Expanded Disability Status Scale (EDSS) scores in patients with relapsing multiple sclerosis (RMS). Methods. This 24-month, phase IV, observational study enrolled 334 patients with RMS who received interferon β-1a 44 μg or 22 μg subcutaneously three times weekly. At each 6-month visit, patients completed the Multiple Sclerosis Quality of Life-54 (MSQOL-54) and site investigators assessed EDSS and recorded relapse occurrence. A generalized linear model procedure was used for multivariable analyses (per protocol) that explored unique associations of EDSS score change and relapse occurrence with MSQOL-54 physical health composite score (PCS) and mental health composite score (MCS). Results. HRQoL improved over 2 years among those who completed the study. Occurrence of ≥1 relapse was significantly associated with lower MSQOL-54 PCS and MCS. Changes in EDSS score were significantly associated with MSQOL-54 PCS, but not MCS. Conclusions. HRQoL assessments, particularly those that examine mental health, may provide information on the general health status of patients with RMS that would not be recognized using traditional clinician-assessed measures of disease severity and activity. This trial is registered with ClinicalTrials.gov; identifier: NCT01141751.

接受皮下干扰素β -1a治疗的多发性硬化症患者,EDSS变化与生理HRQoL相关,而复发与总体HRQoL相关
目标。比较复发性多发性硬化症(RMS)患者与健康相关生活质量(HRQoL)的身心健康维度随时间的变化与复发发生率和扩展残疾状态量表(EDSS)评分变化的关联模式。方法。这项为期24个月的IV期观察性研究纳入了334例RMS患者,他们接受干扰素β-1a 44 μg或22 μg皮下注射,每周3次。在每6个月的随访中,患者完成多发性硬化症生活质量54 (MSQOL-54),现场研究者评估EDSS并记录复发情况。采用广义线性模型程序进行多变量分析(每个方案),探索EDSS评分变化和复发发生率与MSQOL-54身体健康综合评分(PCS)和心理健康综合评分(MCS)的独特关联。结果。在完成研究的患者中,HRQoL在2年内有所改善。复发≥1次的发生率与较低的MSQOL-54 PCS和MCS显著相关。EDSS评分的变化与MSQOL-54 PCS显著相关,而与MCS无关。结论。HRQoL评估,特别是那些检查心理健康的评估,可以提供关于RMS患者一般健康状况的信息,而使用传统的临床评估疾病严重程度和活动的措施无法识别这些信息。该试验已在ClinicalTrials.gov注册;标识符:NCT01141751。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Multiple Sclerosis International
Multiple Sclerosis International CLINICAL NEUROLOGY-
自引率
0.00%
发文量
6
审稿时长
15 weeks
期刊介绍: Multiple Sclerosis International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to all aspects of multiple sclerosis, including clinical neurology, neuroimaging, neuropathology, therapeutics, genetics, neuroimmunology, biomarkers, psychology and neurorehabilitation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信